MXPA05011597A - Derivados de aminopropanol como moduladores del receptor 1-fosfato de esfingosina. - Google Patents
Derivados de aminopropanol como moduladores del receptor 1-fosfato de esfingosina.Info
- Publication number
- MXPA05011597A MXPA05011597A MXPA05011597A MXPA05011597A MXPA05011597A MX PA05011597 A MXPA05011597 A MX PA05011597A MX PA05011597 A MXPA05011597 A MX PA05011597A MX PA05011597 A MXPA05011597 A MX PA05011597A MX PA05011597 A MXPA05011597 A MX PA05011597A
- Authority
- MX
- Mexico
- Prior art keywords
- sphingosine
- receptor modulators
- phosphate receptor
- aminopropanol derivatives
- aminopropanol
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/64—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D263/57—Aryl or substituted aryl radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/141—Esters of phosphorous acids
- C07F9/1414—Esters of phosphorous acids with arylalkanols
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
- C07F9/6539—Five-membered rings
- C07F9/6541—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Abstract
Compuestos de la formula (I): en la que X, a, b, R1, R2, R3, R4 y R5 son como se define en la memoria descriptiva; procesos para su produccion; sus usos, y composiciones farmaceuticas que los contienen.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0309946 | 2003-04-30 | ||
GB0329501A GB0329501D0 (en) | 2003-12-19 | 2003-12-19 | Organic compounds |
GB0329494A GB0329494D0 (en) | 2003-12-19 | 2003-12-19 | Organic compounds |
PCT/EP2004/004572 WO2004096757A1 (en) | 2003-04-30 | 2004-04-29 | Aminopropanol derivatives as sphingosine-1-phosphate receptor modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA05011597A true MXPA05011597A (es) | 2005-12-15 |
Family
ID=33424536
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA05011597A MXPA05011597A (es) | 2003-04-30 | 2004-04-29 | Derivados de aminopropanol como moduladores del receptor 1-fosfato de esfingosina. |
Country Status (10)
Country | Link |
---|---|
US (1) | US7825260B2 (es) |
EP (1) | EP1622866B1 (es) |
JP (1) | JP4638410B2 (es) |
CN (1) | CN1809531B (es) |
AU (1) | AU2004234067B2 (es) |
BR (1) | BRPI0409977A (es) |
CA (1) | CA2523677A1 (es) |
ES (1) | ES2392167T3 (es) |
MX (1) | MXPA05011597A (es) |
WO (1) | WO2004096757A1 (es) |
Families Citing this family (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA05008531A (es) * | 2003-02-11 | 2005-11-17 | Irm Llc | Compuestos biciclicos novedosos y composiciones. |
US7399765B2 (en) * | 2003-09-19 | 2008-07-15 | Abbott Laboratories | Substituted diazabicycloalkane derivatives |
US7638637B2 (en) | 2003-11-03 | 2009-12-29 | University Of Virginia Patent Foundation | Orally available sphingosine 1-phosphate receptor agonists and antagonists |
GB0411929D0 (en) * | 2004-05-27 | 2004-06-30 | Novartis Ag | Organic compounds |
JP5315611B2 (ja) * | 2004-06-23 | 2013-10-16 | 小野薬品工業株式会社 | S1p受容体結合能を有する化合物およびその用途 |
DK1772145T3 (da) | 2004-07-16 | 2011-05-30 | Kyorin Seiyaku Kk | Fremgangsmåde til effektiv anvendelse af medicin og fremgangsmåde til forebyggelse af bivirkninger |
RU2007109207A (ru) | 2004-08-13 | 2008-09-20 | Прикис Фамэсьютикэлс, Инк. (US) | Соединения-модуляторы активности рецептора сфингозин-1-фосфата (варианты), фармацевтическая композиция, содержащая указанные соединения, и способ лечения нарушения, ассоциированного со сфингозин-1-фосфатом |
US7795472B2 (en) | 2004-10-12 | 2010-09-14 | Kyorin Pharmaceutical Co., Ltd. | Process for producing 2-amino-2-[2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]ethyl]-1,3-propanediol hydrochloride and hydrates thereof, and intermediates in the production thereof |
CA2590748A1 (en) | 2004-12-06 | 2006-06-15 | University Of Virginia Patent Foundation | Aryl amide sphingosine 1-phosphate analogs |
GB0504544D0 (en) * | 2005-03-04 | 2005-04-13 | Novartis Ag | Organic compounds |
EP1883402A2 (en) | 2005-04-13 | 2008-02-06 | Astex Therapeutics Limited | Hydroxybenzamide derivatives and their use as inhibitors of hsp90 |
SI1932522T1 (sl) * | 2005-10-07 | 2012-08-31 | Kyorin Seiyaku Kk | Terapevtsko sredstvo za jetrno bolezen, ki vsebuje 2-amino-1,3- propandiolni derivat kot aktivno sestavino |
KR100773765B1 (ko) | 2005-11-24 | 2007-11-12 | 재단법인서울대학교산학협력재단 | 개선된 스핑고신 유사체의 제조 방법 |
MX2008009579A (es) | 2006-01-27 | 2008-09-25 | Univ Virginia | Metodo para el tratamiento de dolor neuropatico. |
TWI389683B (zh) * | 2006-02-06 | 2013-03-21 | Kyorin Seiyaku Kk | A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient |
JP2009526073A (ja) * | 2006-02-09 | 2009-07-16 | ユニバーシティ オブ バージニア パテント ファンデーション | 二環式スフィンゴシン−1−リン酸受容体アナログ |
US7754725B2 (en) | 2006-03-01 | 2010-07-13 | Astex Therapeutics Ltd. | Dihydroxyphenyl isoindolymethanones |
US8097644B2 (en) * | 2006-03-28 | 2012-01-17 | Allergan, Inc. | Indole compounds having sphingosine-1-phosphate (S1P) receptor antagonist |
ES2689484T3 (es) | 2006-07-05 | 2018-11-14 | Fibrotech Therapeutics Pty Ltd | Compuestos terapéuticos |
CA2659599C (en) * | 2006-08-08 | 2014-06-17 | Kyorin Pharmaceutical Co., Ltd. | Amino alcohol derivative and immunosuppressive agent having same as an active ingredient |
CN101501049B (zh) * | 2006-08-08 | 2013-04-24 | 杏林制药株式会社 | 氨基磷酸酯衍生物以及将它们作为有效成分的s1p受体调节剂 |
GB0620259D0 (en) | 2006-10-12 | 2006-11-22 | Astex Therapeutics Ltd | Pharmaceutical compounds |
JP5410285B2 (ja) | 2006-10-12 | 2014-02-05 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
US9730912B2 (en) | 2006-10-12 | 2017-08-15 | Astex Therapeutics Limited | Pharmaceutical compounds |
US8277807B2 (en) | 2006-10-12 | 2012-10-02 | Astex Therapeutics Limited | Pharmaceutical combinations |
WO2008044041A1 (en) | 2006-10-12 | 2008-04-17 | Astex Therapeutics Limited | Pharmaceutical combinations |
JP5528807B2 (ja) | 2006-10-12 | 2014-06-25 | アステックス、セラピューティックス、リミテッド | 複合薬剤 |
AU2007323540A1 (en) * | 2006-11-21 | 2008-05-29 | University Of Virginia Patent Foundation | Hydrindane analogs having sphingosine 1-phosphate receptor agonist activity |
AU2007323618A1 (en) * | 2006-11-21 | 2008-05-29 | University Of Virginia Patent Foundation | Tetralin analogs having sphingosine 1-phosphate agonist activity |
AU2007323557A1 (en) * | 2006-11-21 | 2008-05-29 | University Of Virginia Patent Foundation | Benzocycloheptyl analogs having sphingosine 1-phosphate receptor activity |
CA2684385A1 (en) * | 2007-04-19 | 2008-10-30 | Glaxo Group Limited | Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (s1p) agonists |
AU2008286770A1 (en) * | 2007-08-15 | 2009-02-19 | Biogen Idec Ma Inc. | Bicyclic sphingosine 1-phosphate analogs |
CN101874015A (zh) * | 2007-09-28 | 2010-10-27 | 弗吉尼亚大学专利基金会 | 苄基-环烷基鞘氨醇1-磷酸酯受体调节剂 |
TW200946105A (en) | 2008-02-07 | 2009-11-16 | Kyorin Seiyaku Kk | Therapeutic agent or preventive agent for inflammatory bowel disease containing amino alcohol derivative as active ingredient |
GB0806527D0 (en) | 2008-04-11 | 2008-05-14 | Astex Therapeutics Ltd | Pharmaceutical compounds |
TW201000099A (en) * | 2008-06-20 | 2010-01-01 | Amgen Inc | S1P1 receptor agonists and use thereof |
NZ590377A (en) * | 2008-07-15 | 2011-11-25 | Sanofi Aventis | Oxazolopyrimidines as edg-1 receptor agonists |
MX354134B (es) | 2008-07-23 | 2018-02-14 | Arena Pharm Inc | Derivados de acido 1,2,3,4-tetrahidrociclopenta [b] indol-3-il) acetico sustituidos utiles en el tratamiento de enfermedades autoinmune e inflamatorias. |
US8415484B2 (en) | 2008-08-27 | 2013-04-09 | Arena Pharmaceuticals, Inc. | Substituted tricyclic acid derivatives as S1P1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders |
CN105153188B (zh) * | 2009-10-22 | 2018-06-01 | 法博太科制药有限公司 | 抗纤维化剂的稠环类似物 |
CN102686574A (zh) * | 2009-10-23 | 2012-09-19 | 阿勒根公司 | 作为具有治疗应用的受体调节剂的香豆素化合物 |
UY33181A (es) * | 2010-01-14 | 2011-08-31 | Sanofi Aventis | Derivados de oxazolopirimidina 2,5-sustituidos. |
DK2523960T3 (da) * | 2010-01-14 | 2014-01-20 | Sanofi Sa | Heterocykliske carboxylsyrederivater med en 2,5-substitueret oxazolopyrimidinring |
UY33179A (es) * | 2010-01-14 | 2011-08-31 | Sanofi Aventis | Derivados de ácido carboxílico que comprenden un anillo de oxazolopirimidina 2,5-sustituido. |
EP2528894A1 (en) | 2010-01-27 | 2012-12-05 | Arena Pharmaceuticals, Inc. | Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof |
US9085581B2 (en) | 2010-03-03 | 2015-07-21 | Arena Pharmaceuticals, Inc. | Processes for the preparation of S1P1 receptor modulators and crystalline forms thereof |
CN102260178A (zh) * | 2010-05-25 | 2011-11-30 | 中国医学科学院药物研究所 | 羟基丙二醇类衍生物、其制备方法和其药物组合物与用途 |
RU2013150173A (ru) * | 2011-04-14 | 2015-05-20 | Аллерган, Инк. | Метиламинные производные бициклического фенила как модуляторы рецепторов сфингозин-1-фосфата |
CN103998432A (zh) * | 2011-10-24 | 2014-08-20 | 武田药品工业株式会社 | 双环化合物 |
US9657043B2 (en) | 2012-04-23 | 2017-05-23 | Mitsubishi Tanabe Pharma Corporation | Amine compound and use thereof for medical purposes |
WO2014120764A1 (en) * | 2013-01-29 | 2014-08-07 | Biogen Idec Ma Inc. | S1p modulating agents |
CN105017034B (zh) * | 2014-04-17 | 2019-02-15 | 中国科学院上海药物研究所 | 氨基醇类化合物、其制备方法、包含此类化合物的药物组合物及其用途 |
EP3242666A1 (en) | 2015-01-06 | 2017-11-15 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the s1p1 receptor |
CN108349891B (zh) | 2015-06-22 | 2022-04-05 | 艾尼纳制药公司 | 用于s1p1受体相关病症的化合物的结晶l-精氨酸盐 |
US11014873B2 (en) | 2017-02-03 | 2021-05-25 | Certa Therapeutics Pty Ltd. | Anti-fibrotic compounds |
US11534424B2 (en) | 2017-02-16 | 2022-12-27 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of primary biliary cholangitis |
MX2019009843A (es) | 2017-02-16 | 2020-01-30 | Arena Pharm Inc | Compuestos y metodos para el tratamiento de la enfermedad inflamatoria intestinal con manifestaciones extraintestinales. |
KR102292989B1 (ko) * | 2017-03-29 | 2021-08-26 | 재단법인 아산사회복지재단 | S1pr4를 타겟으로 하는 비알코올성 지방간염 예방 또는 치료용 조성물 |
KR20210074291A (ko) | 2018-09-06 | 2021-06-21 | 아레나 파마슈티칼스, 인크. | 자가면역 및 염증성 장애의 치료에 유용한 화합물 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7112594B2 (en) | 2000-08-09 | 2006-09-26 | Mitsubishi Pharma Corporation | Fused bicyclic amide compounds and medicinal use thereof |
CZ20032560A3 (cs) * | 2001-03-26 | 2003-12-17 | Novartis Ag | Deriváty 2-aminopropanolu, způsob jejich přípravy a farmaceutický prostředek, který je obsahuje |
JP2002316985A (ja) * | 2001-04-20 | 2002-10-31 | Sankyo Co Ltd | ベンゾチオフェン誘導体 |
GB0405289D0 (en) * | 2004-03-09 | 2004-04-21 | Novartis Ag | Organic compounds |
GB0411929D0 (en) * | 2004-05-27 | 2004-06-30 | Novartis Ag | Organic compounds |
-
2004
- 2004-04-29 EP EP04730225A patent/EP1622866B1/en not_active Expired - Lifetime
- 2004-04-29 AU AU2004234067A patent/AU2004234067B2/en not_active Ceased
- 2004-04-29 WO PCT/EP2004/004572 patent/WO2004096757A1/en active Search and Examination
- 2004-04-29 MX MXPA05011597A patent/MXPA05011597A/es active IP Right Grant
- 2004-04-29 US US10/554,557 patent/US7825260B2/en not_active Expired - Fee Related
- 2004-04-29 CN CN2004800171527A patent/CN1809531B/zh not_active Expired - Fee Related
- 2004-04-29 JP JP2006505329A patent/JP4638410B2/ja not_active Expired - Fee Related
- 2004-04-29 ES ES04730225T patent/ES2392167T3/es not_active Expired - Lifetime
- 2004-04-29 CA CA002523677A patent/CA2523677A1/en not_active Abandoned
- 2004-04-29 BR BRPI0409977-0A patent/BRPI0409977A/pt not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
AU2004234067A1 (en) | 2004-11-11 |
EP1622866B1 (en) | 2012-07-25 |
ES2392167T3 (es) | 2012-12-05 |
JP4638410B2 (ja) | 2011-02-23 |
EP1622866A1 (en) | 2006-02-08 |
CA2523677A1 (en) | 2004-11-11 |
BRPI0409977A (pt) | 2006-05-09 |
US7825260B2 (en) | 2010-11-02 |
US20060211656A1 (en) | 2006-09-21 |
CN1809531A (zh) | 2006-07-26 |
AU2004234067B2 (en) | 2008-02-28 |
WO2004096757A1 (en) | 2004-11-11 |
JP2006524662A (ja) | 2006-11-02 |
WO2004096757A8 (en) | 2005-01-27 |
CN1809531B (zh) | 2010-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA05011597A (es) | Derivados de aminopropanol como moduladores del receptor 1-fosfato de esfingosina. | |
MXPA05011596A (es) | Derivados de amino-propanol como modulador de receptor de esfingosina-1-fosfato. | |
MXPA05013348A (es) | Derivados de amino-propanol como moduladores del receptor de esfingosina-1-fosfato. | |
PL1753712T3 (pl) | Pochodne aminopropanolu | |
PT1660449E (pt) | Derivados de aminopropanol | |
TW200616995A (en) | Novel compounds | |
TW200505920A (en) | Organic compounds | |
TW200801003A (en) | Novel compounds | |
TW200732335A (en) | Organic compounds | |
TW200635917A (en) | Novel compounds | |
AU2002351124A1 (en) | Pyrazoles-pyrimidine fungicides | |
HK1125358A1 (en) | Substituted cyclohexylmethyl derivatives | |
TW200745084A (en) | Novel compounds | |
TW200635916A (en) | Compounds | |
MX2007007720A (es) | Derivados de pirrolidinio como receptores m3 muscarinicos. | |
PL1904482T3 (pl) | Pochodne indolilomaleimidowe | |
MX2010009022A (es) | Derivados 16 alfa, 17 alfa-acetal glucocorticoesteroideos y su uso. | |
TW200732337A (en) | Organic compounds | |
TW200740781A (en) | Novel compounds | |
SE0400850D0 (sv) | Novel Compounds | |
MXPA05013823A (es) | Derivados de pirrolidinio y piperidino como ligandos para el receptor m3 muscarinico. | |
GB0428418D0 (en) | Organic compounds | |
TW200722418A (en) | Novel compounds | |
GEP20084502B (en) | Piperazine compounds, a process for their preparation and pharmaceutical compositions containing them | |
NO20081862L (no) | Alkylsulfoksidkinoliner som NK-3-reseptorligander |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration | ||
HH | Correction or change in general |